Idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis is a rapidly progressive illness of unknown cause characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. Treatment at present remains largely supportive, with evidence that patients' satisfaction and survival may be improved by referral to centers specializing in the evaluation of interstitial lung diseases. Although no drug therapy has clearly been demonstrated to benefit patients with idiopathic pulmonary fibrosis, a number of novel investigational agents hold promise for future study. Given the poor prognosis associated with idiopathic pulmonary fibrosis, patients should be referred to regional centers of expertise for enrollment in therapeutic clinical trials or for lung transplantation.
Gross
T J
TJ
Department of Internal Medicine, University of Iowa College of Medicine and Veterans Affairs Medical Center, Iowa City, USA.
Hunninghake
G W
GW
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018450:Disease Progression; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging; D016040:Lung Transplantation; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D011859:Radiography; D013256:Steroids
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D005343:Fibrinolytic Agents; D013256:Steroids